Technical Analysis for CUE - Cue Biopharma, Inc.

Grade Last Price % Change Price Change
grade F 11.07 -0.72% -0.08
CUE closed down 0.72 percent on Thursday, July 19, 2018, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
1 Watcher
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong N/A Down Down
See historical CUE trend table...

Date Alert Name Type % Chg
Jul 19 Narrow Range Bar Range Contraction 0.00%
Jul 19 NR7 Range Contraction 0.00%
Jul 19 Stochastic Reached Oversold Weakness 0.00%
Jul 19 Inside Day Range Contraction 0.00%
Jul 19 Down 3 Days in a Row Weakness 0.00%
Jul 19 Down 4 Days in a Row Weakness 0.00%
Jul 19 Down 5 Days in a Row Weakness 0.00%
Jul 19 Oversold Stochastic Weakness 0.00%
Jul 18 Hammer Candlestick Bullish -0.72%
Jul 18 Down 3 Days in a Row Weakness -0.72%

Older signals for CUE ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Track My Stocks
Configure default chart indicators
Basic chart:
Profile
  • Earnings date: 2018-08-13
Cue Biopharma Inc is a biopharmaceutical company developing a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders.
Is CUE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Jul 12 Cue Biopharma Produces Immuno-STAT™ Biologic Candidate for Treatment of Autoimmune Disease Under Collaboration and License Agreement with Merck
Jul 2 The Week Ahead: Tariffs Dominate The Headlines In Slow Market Week
Jun 28 Cue Biopharma Strengthens Board of Directors with Addition of Fred Driscoll to Chair Audit Committee
May 10 Cue Biopharma to Host Investor Business Update Call and Webcast
May 1 Benzinga's Daily Biotech Pulse: Karyopharm's STORM Study, Inogen Rallies On Earnings
Apr 25 Cue Biopharma Announces Appointment of Anish Suri, Ph.D. as Chief Scientific Officer
Apr 5 Cue Biopharma to Present at Bloomberg Biotech Innovations Conference
Feb 12 The Week Ahead: Earnings, FDA Actions, And Industry Conferences To Watch
Feb 7 Cue Biopharma to Present at BIO CEO & Investor Conference
Feb 6 Cue Biopharma: Too Early For This Very Exciting Platform
See more CUE news...
Indicators
Indicator Value
52 Week High 17.99
52 Week Low 10.3
Average Volume 100,400
200-Day Moving Average 0.0
50-Day Moving Average 12.9284
20-Day Moving Average 11.8865
10-Day Moving Average 11.489
Average True Range 0.6424
ADX 26.93
+DI 14.8504
-DI 22.8767
Chandelier Exit (Long, 3 ATRs ) 11.4628
Chandelier Exit (Short, 3 ATRs ) 12.7072
Upper Bollinger Band 12.9914
Lower Bollinger Band 10.7816
Percent B (%b) 0.13
BandWidth 18.590838
MACD Line -0.4845
MACD Signal Line -0.4531
MACD Histogram -0.0313
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.54
Resistance 3 (R3) 11.52 11.34 11.46
Resistance 2 (R2) 11.34 11.22 11.35 11.43
Resistance 1 (R1) 11.21 11.15 11.28 11.23 11.41
Pivot Point 11.03 11.03 11.07 11.04 11.03
Support 1 (S1) 10.90 10.91 10.97 10.92 10.73
Support 2 (S2) 10.72 10.84 10.73 10.71
Support 3 (S3) 10.59 10.72 10.68
Support 4 (S4) 10.61